2021
DOI: 10.1007/s00221-021-06176-8
|View full text |Cite
|
Sign up to set email alerts
|

Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
16
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 41 publications
(17 citation statements)
references
References 85 publications
1
16
0
Order By: Relevance
“…All the treatment groups were associated with significantly lower tau levels than the positive control group, with metformin and insulin glargine being the most effective. This finding is similar to that reported in a previous study on metformin [55].…”
Section: Plos Onesupporting
confidence: 93%
“…All the treatment groups were associated with significantly lower tau levels than the positive control group, with metformin and insulin glargine being the most effective. This finding is similar to that reported in a previous study on metformin [55].…”
Section: Plos Onesupporting
confidence: 93%
“…Therefore, increasing the availability or sensitivity to insulin at the brain level could be a possible therapeutic alternative for the management of AD patients [ 116 ]. In fact, administration of oral antidiabetic drugs, and more specifically of metformin, has been shown to have a neuroprotective, anti-inflammatory and antioxidant action [ 117 ]. In addition, one of the therapeutic approaches under study is the administration of intranasal insulin [ 118 ].…”
Section: Resultsmentioning
confidence: 99%
“…On the other hand, AMPK-related signaling is activated in APP/PS1 transgenic AD mouse neurons, and AMPK inhibitors reduces ALR-related protein expression levels, thereby ameliorating memory deficits ( Du et al, 2019 ). Oliveira et al found that metformin activation of AMPK can reduce neuroinflammation and neuronal damage, improve cognition, and improve the symptoms of AD ( Oliveira et al, 2021 ). But the underlying molecular/cellular mechanisms needed further clarification.…”
Section: Metformin and Neurodegenerative Diseasesmentioning
confidence: 99%